Literature DB >> 9042037

A simple device for the exposure of animals to infectious microorganisms by the airborne route.

R J Phillpotts1, T J Brooks, C S Cox.   

Abstract

In order to evaluate prophylaxis and therapy for individuals infected with pathogens by the airborne route, we have designed and built a simple apparatus in which small laboratory animals may be exposed to aerosols of infectious microorganisms. Animals are kept in a chamber closed by a HEPA filter and exposed to the pathogen aerosolized using a Collison nebulizer. Air in the exposure chamber may be sampled to show that the infectious agent is present but the dose of agent must be expressed as 50% effective doses determined by titration. An effective dose may be defined by whatever criteria are chosen to judge disease. Using this apparatus we have shown that St Louis encephalitis (SLE) virus is infectious for mice by the airborne route. These data support the idea that there may be significant hazard to personnel exposed to aerosols of infectious SLE after a laboratory accident.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9042037      PMCID: PMC2808774          DOI: 10.1017/s0950268896007157

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  9 in total

Review 1.  Methods for sampling of airborne viruses.

Authors:  Daniel Verreault; Sylvain Moineau; Caroline Duchaine
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

2.  Pegylated alpha interferon is an effective treatment for virulent venezuelan equine encephalitis virus and has profound effects on the host immune response to infection.

Authors:  R A Lukaszewski; T J Brooks
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice.

Authors:  Emily K Forbes; Clare Sander; Edward O Ronan; Helen McShane; Adrian V S Hill; Peter C L Beverley; Elma Z Tchilian
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

4.  Chemokine gene expression in lung CD8 T cells correlates with protective immunity in mice immunized intra-nasally with Adenovirus-85A.

Authors:  Lian N Lee; Dilair Baban; Edward O Ronan; Jiannis Ragoussis; Peter C L Beverley; Elma Z Tchilian
Journal:  BMC Med Genomics       Date:  2010-10-13       Impact factor: 3.063

5.  Improved efficacy of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus.

Authors:  Amanda J Williams; Lyn M O'Brien; Robert J Phillpotts; Stuart D Perkins
Journal:  Virol J       Date:  2009-07-31       Impact factor: 4.099

6.  Targeting of the Nasal Mucosa by Japanese Encephalitis Virus for Non-Vector-Borne Transmission.

Authors:  Roman O Braun; Panagiota Milona; Obdulio García-Nicolás; Marta Lewandowska; Ronald Dijkman; Marco P Alves; Artur Summerfield
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

7.  Aerosol and Contact Transmission Following Intranasal Infection of Mice with Japanese Encephalitis Virus.

Authors:  Chunxia Chai; Rachel Palinski; Yixuan Xu; Qiao Wang; Sanjie Cao; Yi Geng; Qin Zhao; Yiping Wen; Xiaobo Huang; Qiguai Yan; Xiaoping Ma; Xintian Wen; Yong Huang; Xinfeng Han; Wenjun Ma; Rui Wu
Journal:  Viruses       Date:  2019-01-21       Impact factor: 5.048

8.  A method to provide improved dose-response estimates for airborne pathogens in animals: an example using porcine reproductive and respiratory syndrome virus.

Authors:  J R Hermann; C A Muñoz-Zanzi; J J Zimmerman
Journal:  Vet Microbiol       Date:  2008-07-25       Impact factor: 3.293

9.  Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.

Authors:  Eung-Jun Im; Narcís Saubi; Goretti Virgili; Clare Sander; Denise Teoh; Jose M Gatell; Helen McShane; Joan Joseph; Tomás Hanke
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.